What Exvastat does

Exvastat is a preclinical-stage pharmaceutical company founded in 2016 and headquartered in Cambridge, United Kingdom. The company operates with a very small team of 1-10 employees and is classified as private, indicating an early-stage drug discovery operation that has not yet reached clinical trials or commercialization.

The company's activities are positioned within the early-stage pharmaceutical R&D value chain, where it likely focuses on target identification, compound development, and preclinical validation. Its capital structure reflects this stage: an initial 2017 funding round led by Cambridge Innovation Capital (a specialist UK life sciences investor) was followed in May 2020 by approximately $3.9 million from the Innovative Medicines Initiative (IMI), the EU's public-private partnership for pharmaceutical research. The IMI funding in particular suggests integration into multi-partner European preclinical research consortia.

Exvastat is led by co-founder and CEO David Cavalla, supported by co-founder Andrew McElroy as Strategic Project Manager, CFO Stuart Gibson, and Non-Executive Director Julian Gilbert. With no disclosed revenue, pricing model, commercial products, or named customers, the company's business model at present is grant- and equity-funded preclinical R&D rather than product sales; future revenue mechanics will depend on out-licensing, partnerships, or eventual clinical progression of any candidates.

Name

Exvastat

Website

https://exvastat.com

Company type

Private

Founded year

2016

Headcount range

1–10 employees

Short description

Exvastat is a preclinical-stage, privately held pharmaceutical company founded in 2016 in Cambridge, UK, developing early-stage drug candidates with a small founder-led team funded by Cambridge Innovation Capital and the EU's Innovative Medicines Initiative.

Ownership category

akta.pro rank

Product category

Preclinical Pharmaceutical Research

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Preclinical Development (Pharmacology, PK/PD, ADME, Toxicology) (HLAIALAC)

Keywords

• Preclinical drug development
• Pharmaceutical research
• Drug discovery services
• Early-stage biopharma
• Small molecule therapeutics

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Core offering

Exvastat is a preclinical-stage pharmaceutical company that conducts early-stage drug discovery and development research. Founded in 2016 and based in Cambridge, United Kingdom, the company operates with a small team (1-10 employees) focused on advancing innovative therapeutic candidates prior to clinical trials.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Official platformsunclearStrategic or Co-development PartnerHarumslot works with official platforms to provide fast access with secure and trusted connections. The platform collaborates with official partners to ensure rapid and safe access for users.

Recent moves2 records

Expansion highlights3 records

Direct peers

• Crescendo Biologics: Cambridge, UK-based preclinical-stage biotech developing T-cell engager biologics. Comparable to Exvastat in Cambridge location, preclinical stage, and small-team operating model focused on a defined therapeutic platform.
• Bicycle Therapeutics: Cambridge, UK-headquartered clinical-stage biotech developing novel therapeutics based on bicyclic peptide scaffolds. Comparable to Exvastat as a Cambridge-rooted, small-team pharmaceutical company that progressed from preclinical to clinical development — a relevant trajectory benchmark for Exvastat's forward path.
• Mission Therapeutics: Cambridge, UK-based preclinical/early-clinical biotech developing small-molecule drugs targeting deubiquitinating enzymes. Comparable to Exvastat in Cambridge location, small-team operating structure, and earlier-stage development profile.
• PhoreMost: Cambridge, UK-based preclinical drug-discovery biotech using a proprietary target-identification platform to generate novel therapeutic programs. Highly comparable to Exvastat in geography, stage, and small-team operating model, with a similar early-capital profile.

Broad incumbents

• AstraZeneca: Global pharmaceutical company with a major R&D footprint in Cambridge, UK. Comparable to Exvastat as a Cambridge-anchored pharma operator and a likely IMI-consortium industry partner; represents the type of strategic acquirer or partner relevant to Exvastat's forward optionality.
• Charles River Laboratories: Large contract research organization providing preclinical discovery and development services across small molecules and biologics. Comparable to Exvastat as a counterpart for outsourced preclinical work and as a benchmark for the broader preclinical-services value chain Exvastat operates within.
• GSK: Global pharmaceutical company headquartered in the UK with a major Cambridge-area R&D presence and historical involvement in IMI consortia. Comparable to Exvastat as a Cambridge-anchored pharma operator and a likely consortium/partner counterpart for IMI-funded preclinical programs.
• Evotec: Global drug-discovery and development services company with deep operations in small-molecule and biologic preclinical work. Comparable to Exvastat as a potential outsourced-discovery counterpart and as a benchmark for capital-efficient preclinical development models.

Emerging players

• RxCelerate: Cambridge, UK-based drug-development CRO focused on preclinical and translational work for early-stage biotechs. Comparable to Exvastat as a Cambridge-ecosystem service provider to similar small preclinical pharma companies and as a benchmark for outsourced preclinical execution.
• Domainex: UK-based CRO with integrated drug-discovery services and a co-discovery model that has produced spin-out biotechs. Comparable to Exvastat as a Cambridge-ecosystem participant offering preclinical services and as an emerging alternative model for asset development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/exvastat

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exvastat